Highlights Biogen Inc.

Stocks

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-07-17 pm EDT			5-day change	1st Jan Change
205.99 ^USD	-1.40%		+3.43%	+17.05%

Jul. 15	Biogen Inc. Appoints Michael J. Parini as Chief Legal Officer, Effective August 3, 2026	CI
Jul. 14	Biogen Inc. Presents at Alzheimer?s Association International Conference (AAIC Meeting) 2026, Jul-12-2026 through Jul-15-2026

Highlights

Jul. 14	Biogen Inc. Presents Phase 2 CELIA Data Demonstrating Clinical Outcomes And Tau Reduction With Diranersen In Early Alzheimer?s Disease	CI
Jul. 14	Bioarctic AB Partner Eisai Receives Fda Approval for Leqembi Iqlik Subcutaneous Injection as Starting Dose for Early Alzheimer's Disease	CI
Jul. 13	FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug	RE
Jul. 01	Biogen Says Research, Milestone Charges to Reduce Earnings in Q2, Q3	MT
Jun. 29	Biogen To Present New Data Across Its Alzheimer?s Disease Portfolio At AAIC 2026	CI
Jun. 26	Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout	RE
Jun. 18	Biogen Advancing Diranersen Alzheimer's Drug Into Phase 3 Shows Confidence, Morgan Stanley Says	MT
Jun. 18	Biogen to Acquire RayThera in Up to $1 Billion Deal to Expand Immunology Pipeline	MT
Jun. 18	Biogen to Acquire Biotechnology Firm RayThera for Up to $1 Billion	MT
Jun. 17	Biogen targets immunology growth with $1 billion RayThera deal	RE
Jun. 17	Biogen to acquire RayThera for $1 billion	RE
Jun. 16	Biogen Inc. entered into a definitive agreement to acquire RayThera, Inc. from Foresite Capital Management, LLC, OrbiMed Advisors LLC, TTM Capital and others for $1 billion.	CI
Jun. 04	Biogen Receives FDA Breakthrough Therapy Designation for Salanersen for Spinal Muscular Atrophy	CI
May. 27	Italy probes Biogen for allegedly hindering sales of rival's MS drug	RE
May. 27	Italian Competition Watchdog Launches Probe into Biogen Over Alleged Market Abuse	MT
May. 27	Biogen Faces Italian Antitrust Probe Over Multiple Sclerosis Drug Competition	MT
May. 27	Italy's antitrust regulator opens probe into US Biogen over alleged dominant position	RE
May. 14	Biogen Announces Topline Results from Phase 2 Celia Study of Diranersen	CI
May. 14	Biogen Inc. Enters Into USD 2,000 Million Unsecured Term Loan Credit Agreement	CI
May. 14	Biogen to advance experimental Alzheimer's drug despite mid-stage trial miss	RE
May. 14	Biogen Announces Topline Results from Phase 2 Celia Study of Diranersen	CI
May. 08	Biogen Says FDA Extends Priority Review Period for Leqembi Iqlik by 3 Months	MT
Apr. 29	Biogen beats profit expectations as demand for newer rare-disease drugs fuel growth	RE
Apr. 29	Biogen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 29	Biogen outlook FY adjusted EPS $14.25 to $15.25 vs IBES estimate $15.04	RE